13-113129564-CT-TTGCTCATACGAAGAGGCCC
Position:
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM2PM4PP3PP5_Moderate
The NM_000504.4(F10):c.183_184delCTinsTTGCTCATACGAAGAGGCCC(p.Cys62_Ser63insSerTyrGluGluAlaArg) variant causes a conservative inframe insertion, synonymous change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★).
Frequency
Genomes: not found (cov: 32)
Consequence
F10
NM_000504.4 conservative_inframe_insertion, synonymous
NM_000504.4 conservative_inframe_insertion, synonymous
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 7.86
Genes affected
F10 (HGNC:3528): (coagulation factor X) This gene encodes the vitamin K-dependent coagulation factor X of the blood coagulation cascade. This factor undergoes multiple processing steps before its preproprotein is converted to a mature two-chain form by the excision of the tripeptide RKR. Two chains of the factor are held together by 1 or more disulfide bonds; the light chain contains 2 EGF-like domains, while the heavy chain contains the catalytic domain which is structurally homologous to those of the other hemostatic serine proteases. The mature factor is activated by the cleavage of the activation peptide by factor IXa (in the intrisic pathway), or by factor VIIa (in the extrinsic pathway). The activated factor then converts prothrombin to thrombin in the presence of factor Va, Ca+2, and phospholipid during blood clotting. Mutations of this gene result in factor X deficiency, a hemorrhagic condition of variable severity. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing to generate mature polypeptides. [provided by RefSeq, Aug 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PM4
Nonframeshift variant in NON repetitive region in NM_000504.4.
PP3
No computational evidence supports a deleterious effect, but strongly conserved according to phyloP
PP5
Variant 13-113129564-CT-TTGCTCATACGAAGAGGCCC is Pathogenic according to our data. Variant chr13-113129564-CT-TTGCTCATACGAAGAGGCCC is described in ClinVar as [Likely_pathogenic]. Clinvar id is 3575773.Status of the report is criteria_provided_single_submitter, 1 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
F10 | NM_000504.4 | c.183_184delCTinsTTGCTCATACGAAGAGGCCC | p.Cys62_Ser63insSerTyrGluGluAlaArg | conservative_inframe_insertion, synonymous_variant | 2/8 | ENST00000375559.8 | NP_000495.1 | |
F10 | NM_001312674.2 | c.183_184delCTinsTTGCTCATACGAAGAGGCCC | p.Cys62_Ser63insSerTyrGluGluAlaArg | conservative_inframe_insertion, synonymous_variant | 2/7 | NP_001299603.1 | ||
F10 | NM_001312675.2 | c.183_184delCTinsTTGCTCATACGAAGAGGCCC | p.Cys62_Ser63insSerTyrGluGluAlaArg | conservative_inframe_insertion, synonymous_variant | 2/8 | NP_001299604.1 | ||
F10-AS1 | NR_126424.1 | n.41+441_41+442delAGinsGGGCCTCTTCGTATGAGCAA | intron_variant |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Likely pathogenic
Submissions summary: Pathogenic:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Hereditary factor X deficiency disease Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 28, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.